Tissue Sodium in Patients With Psoriasis (TSS1)

Charité University Medicine Berlin

Status

Completed

Conditions

Healthy

Psoriasis Vulgaris

Treatments

Diagnostic Test: 23Na Magnetic resonance imaging

Study type

Observational

Funder types

Other

Identifiers

NCT04095130

ChariteU-ECRC-TSS1

Details and patient eligibility

About

Sodium can be buffered in the skin, which mechanism is altered during aging and in certain diseases such as hypertension. High salt environment can promote autoimmunity by expanding pathogenic IL-17 producing T helper (Th17) cells. Psoriasis is a relapsing and remitting inflammatory autoimmune disease affecting the skin and joints and involves proinflammatory Th17 cells. Here we tested the hypothesis if psoriatic skin has a higher sodium content in humans.

Full description

The cytokine interleukin-17A (IL-17A) is a crucial player in the pathogenesis of the autoimmune disease of psoriasis. This neutrophil recruiting cytokine is produced by IL-17A producing CD4+ T cells (Th17) and gamma/delta T cells of the skin and evokes an inflammation circuit finally leading to the classical clinical picture of psoriasis with hyper- and parakeratosis, erythema, scaling and neutrophil abscess formation.

Besides genetic factors, lifestyle factors are relevant and decide if an autoimmune disease becomes manifest. It was shown previously that increased salt (sodium chloride, NaCl) concentrations boost the induction of murine and human Th17 cells. However, more - and also clinical - studies are needed to understand the correlation between salt content and IL-17A in autoimmune diseases.

This study investigates the hypothesis if skin sodium content in human psoriasis is increased in order to get further insight into the IL-17A-salt-interplay.

Enrollment

56 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age: 18-80
Body mass index (BMI) 18.5- 40 kg/m2
Glomerular filtration rate >60 ml/min/1.73m2

Exclusion criteria

Diagnosed or treated hypertension and/or blood pressure above 140/90 at screening
Palpable peripheral oedema during phyisical examination at screening
Any type of diabetes mellitus and/or HgbA1c>6.5% at screening
Subjects with a thyroid-stimulating hormone >4.2 mU/L at screening
Psoriasis patients treated with systemic corticosteroids, chemotherapy agent (methothrexate) or with any kind of biologics/biosimilars
Subjects with acute disease
Pregnant or lactating women
Metal or medical device implant in the body
Tattoo on the lower extremities
Subjects with a history of drug or alcohol abuse
Subjects who are legal incapacitated or their circumstances do not enable the patient to fully understand the nature, significance and scope of this study.